supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 4 years ago
Research Papers that Mention the Interaction
“ Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a chief mechanism influencing tumor growth.”
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.“ Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases.”
“ Sorafenib … tyrosine and serine/threonine kinases (vascular endothelial growth factor (VEGF) receptor 2 and 3, platelet derived growth factor (PDGF) receptor B-Raf, Raf-1, Flt3, … include diarrhea, hypertension, fatigue, and cutaneous lesions (facial and scalp erythema, focal acral erythema/acral erythrodysesthesia/hand-foot syndrome, alopecia, and splinter hemorrhages).”
“Up to 8-fold SFB dose-dependent (5-15 μM) decrease in phosphorylation of RIN1 at tyrosine 36 , but not in total RIN1 expression, was observed.”
Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma.
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback